Clinical Trial Update: PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating PET-directed therapy using pembrolizumab plus combination chemotherapy for previously untreated classical Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Northwestern University | Conditions: Classical Hodgkin Lymphoma, Lymphocyte-Depleted Classical Hodgkin Lymphoma | Phase 2 | Status: UNKNOWN | Results posted: 2020-07-15